This is a video synopsis/summary of an Insights involving Allison Wheeler, MD. Wheeler addresses the nuanced considerations for implementing prophylaxis in patients with mild to moderate hemophilia A, ...

Methods We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses ...

Findings showed concizumab-treated patients had an 86% reduction in annualized bleeding rate compared with no prophylaxis. The Food and Drug Administration (FDA) has approved Alhemo ® (concizumab-mtci ...

Please provide your email address to receive an email when new articles are posted on . Concizumab prophylaxis led to lower annualized bleeding rates than no prophylaxis. Treatment with concizumab ...

The urinary antiseptic methenamine hippurate (Hiprex) was non-inferior to antibiotic prophylaxis in women with a history of recurrent urinary tract infections (UTI), according to results from the ...

Please provide your email address to receive an email when new articles are posted on . Once-monthly fitusiran prophylaxis improved outcomes compared with on-demand treatment for patients with severe ...

Understand key factors influencing hemophilia A treatment decisions and explore the impact of prophylactic vs on-demand therapy on efficacy, safety, and patient outcomes, including joint health, ...

Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...